PACTR202005582198497Other2 期
A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa. DAIDS DOCUMENT ID 12045
Division of AIDS0 个研究点目标入组 82 人开始时间: 2020年5月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- Female
入选标准
- •Inclusion criteria
- •General and Demographic Criteria
- •1. Age of 18 to 40 years
- •2. Access to a participating CRS and willingness to be followed for the planned duration of the study
- •3. Ability and willingness to provide informed consent
- •4. Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first infusion with verbal demonstration of understanding of all questionnaire items answered incorrectly
- •5. Agrees not to enroll in another study of an investigational research agent for the duration of the participant’s trial participation
- •6. Good general health as shown by medical history, physical exam, and screening laboratory tests
- •HIV-Related Criteria:
- •7. Willingness to receive HIV test results
- •8. Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling
- •9. Persons born Female (assigned female sex at birth) and identifying as female, who, in the 6 months prior to randomization, has had vaginal and/or anal intercourse with a male partner
排除标准
- •Exclusion criteria
- •1. Investigational research agents received within 30 days before first infusion
- •2. Body mass index (BMI) = 40
- •3. Pregnant or breastfeeding
- •4. Any reactive, indeterminate, or positive HIV test, even if subsequent testing indicates that the individual is not HIV infected, except as permitted by the HVTN 703/HPTN 081 PSRT
- •5. HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 703/HPTN 081 PSRT will determine eligibility on a case-by-case basis.
- •Immune System
- •6. Serious adverse reactions to VRC01 formulation components such as sodium citrate, sodium chloride, and L-arginine hydrochloride, including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.
- •7. Autoimmune disease, including Type I diabetes mellitus (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require consistent immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate reactogenicity and AE assessments)
- •8. Immunodeficiency syndrome
- •Clinically significant medical conditions
- •9. Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
- •? Any contraindication to repeated infusions or blood draws, including inability to establish venous access;
- •? A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer’s health or well-being during the study period; or
- •A condition or process for which signs or symptoms could be confused with reactions to VRC01.
- •10. Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or infusion reactions, or a volunteer’s ability to give informed consent
- •11. Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
- •12. Asthma, other than mild, well-controlled asthma
- •13. Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
- •14. Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator’s estimation, has a reasonable assurance of sustained cure. or who is unlikely to experience recurrence of malignancy during the period of the study)
- •15. Seizure disorder: History of seizure(s) within past three years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
- •16. History of hereditary angioedema, acquired angioedema, or idiopathic angioedema
- •17. History of receiving transplantation of life-saving organs or tissue (includes heart, kidney, pancreas, lungs, liver, and intestines)
- •18. Known hepatic or renal dysfunction
研究者
相似试验
进行中（未招募）
不适用
TRIAL TO ASSESS THE EFFICACY OF LENVATINIB IN METASTATIC NEUROENDOCRINE TUMORS (TALENT STUDY).?EUCTR2015-001467-39-ESGETNE (Grupo Español de Tumores Neuroendocrinos)110
招募中
不适用
Study to evaluate safety and efficacy of Lifeliver in acute or acute-on-chronic liver failure patientsDiseases of the digestive systemKCT0003748HLB CE40
进行中（未招募）
2 期
A study to test a new type of treatment for blood cancer. In this new treatment the blood cells ofpatients are modified to kill cancer cell on their own.CTRI/2022/03/041162Immuneel Therapeutics Private Limited
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancer.MedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006289Term: Benign and malignant breast neoplasmsSystem Organ Class: 100000004872MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2021-005238-40-ITEQRx International, Inc.100
进行中（未招募）
1 期
Clinical study to review how safe and how effective IMR-687 is in subjects with Sickle Cell DiseaseMedDRA version: 20.0Level: PTClassification code 10043395Term: Thalassaemia sickle cellSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-004471-39-ITIMARA Inc.99